Authors
Latest:
Diffuse Hepatic Infiltration by Metastatic MelanomaMelanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.
Latest:
Dr. Kelly Hunt on the Role of Surgery in Metastatic Breast CancerCancer Network spoke with Kelly Hunt, MD, professor and chair of the department of breast surgical oncology at the MD Anderson Cancer Center in Houston, about the role of surgery in metastatic breast cancer.
Latest:
Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon CancerThis case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
Latest:
Management of Steroid-Refractory Immune-Related Adverse EventsThe increasing utilization of these immune checkpoint inhibitors has presented new of immune-related adverse events that have proven to be extremely challenging to manage.
Latest:
Management of Steroid-Refractory Immune-Related Adverse EventsThe increasing utilization of these immune checkpoint inhibitors has presented new of immune-related adverse events that have proven to be extremely challenging to manage.
Latest:
HPV and the Immune System in Head and Neck Cancers: Therapeutic ConsiderationsA review of the role of immune therapy in HPV-associated head and neck squamous cell carcinoma, along with the evidence and perspective behind differing therapeutic considerations.
Latest:
Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the BrainBrain metastasis is common in breast cancer and often has a poor prognosis, but there are several ways to manage brain metastasis in breast cancer including focal therapies as well as systemic options for specific populations, including emerging and novel therapies.
Latest:
Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the BrainBrain metastasis is common in breast cancer and often has a poor prognosis, but there are several ways to manage brain metastasis in breast cancer including focal therapies as well as systemic options for specific populations, including emerging and novel therapies.
Latest:
Pediatric Acute Lymphoblastic LeukemiaONCOLOGY discussed therapy options, including chimeric antigen receptor (CAR)-T-cell therapies for pediatric acute lymphoblastic leukemia (ALL), with Susan R. Rheingold, MD, Medical Director of the Oncology Outpatient Clinic and attending physician with the Cancer Center at Children’s Hospital of Philadelphia.
Latest:
Monitoring for Thyroid Cancer RecurrenceAlan N. Peiris, MD spoke with ONCOLOGY about guidelines and strategies for treating patients who have had thyroid cancer.
Latest:
Erdafitinib in the Treatment of Metastatic Urothelial CarcinomaFrancisco Castro-Alonso, MD, and colleagues describe the effects of the use of erdafitinib in a patient with metastatic urothelial bladder cancer.
Latest:
What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?
Latest:
What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?
Latest:
Black, Elderly Patients Less Likely to Receive Treatment for Lung CancerAbout a fifth of patients with lung cancer in the United States receive no treatment at all, while approximately 6 in 10 receive the minimal treatments recommended by the National Comprehensive Cancer Network.
Latest:
2019 World Conference Of Lung Cancer Round-UpFive notable abstracts from the 2019 World Conference on Lung Cancer (WCLC).
Latest:
67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant PotentialSTUMP: Elevated PSA, family history, risk factors, and clinical findings. What is the next step in this case? Experts weigh in.
Latest:
Median Lobe Urethral Embolus After Focal Ablation of Gleason 7 Prostate CancerThis is the case of a man, aged 56 years, who presented with urinary intermittency, frequency, urgency, and dysuria 5 months after undergoing focal laser ablation (FLA) of Gleason 3 + 4 = 7 prostate cancer (PC).
Latest:
67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant PotentialSTUMP: Elevated PSA, family history, risk factors, and clinical findings. What is the next step in this case? Experts weigh in.
Latest:
Biliary Cancer: Current Multimodality Treatment and Future DirectionsClinicians discuss appropriate evaluation and choice of management strategies for cholangiocarcinoma.
Latest:
Biliary Cancer: Current Multimodality Treatment and Future DirectionsClinicians discuss appropriate evaluation and choice of management strategies for cholangiocarcinoma.
Latest:
Therapy Options for Patients With Hepatocellular CarcinomaTherapy options for patients with hepatocellular carcinoma (HCC), including a newly approved therapy for a subpopulation of patient.
Latest:
Patient Survival Rates in High-Grade Spinal MeningiomaResearchers recently looked at differences in survival time between patients with grade II and grade III spinal meningioma.
Latest:
Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?Metastasis-directed therapy with stereotactic ablative radiotherapy has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer.
Latest:
Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?Metastasis-directed therapy with stereotactic ablative radiotherapy has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer.
Latest:
OncView™ Podcast: Updates in Managing Extensive-Stage Small Cell Lung CancerThis special edition of the “Oncology Peer Review On-The-Go” dives into recent updates and important treatment strategies for extensive-stage SCLC management.
Latest:
Classifying DLBCL Subtypes for Optimal TreatmentJennifer Crombie, MD, discusses classification of diffuse large B-cell lymphoma (DLBCL) into distinct subtypes and treatment decisions based on molecular classifications.
Latest:
Mutations and the Importance of Genetic TestingDr. Allison W. Kurian discusses a new breast cancer study that analyzed the mutations present in breast tumors, and about emerging targeted therapy options.
Latest:
Sonrotoclax/Zanubrutinib Combo Elicits Deep Responses for Untreated CLL/SLLFor patients with CLL and SLL, sonrotoclax with zanubrutinib yielded high rates of overall response in the phase 1/1b BGB-11417-101 study.
Latest:
PFS Significantly Improves With Acalabrutinib Regimen in Untreated CLLAcalabrutinib-based treatment also improves overall survival vs standard chemoimmunotherapy in the phase 3 AMPLIFY trial.
